October 27, 2016
Sunovion encouraged by schizophrenia drug test
Sunovion is headquartered in Marlborough.
Marlborough drugmaker Sunovion Pharmaceuticals announced Thursday that clinical tests for its new drug to treat adolescents with schizophrenia is showing positive signs.
Sunovion said a six-week study of the drug Latuda showed statistically significant improvement in symptoms of young adults suffering from the mental health disease. Test subjects were given either a lower dose of 40 milligrams per day, a higher dose of 80 milligrams per day or a placebo.
In addition to treating symptoms, Latuda was generally well tolerated by both dose groups with 16 percent showing drowsiness, 13 percent showing nausea, 9 percent experiencing restlessness and 8 percent reporting vomiting.
WBJ Web Partners
Most Recent
Most Recent
0 Comments